Debate:
The Optimal Duration of DAPT

Claudia Bucci
Clinical Coordinator, Cardiovascular Diseases
Department of Pharmacy, Sunnybrook Health Sciences Centre

19th Annual Contemporary Therapeutic Issues in Cardiovascular Disease
May 14, 2016

DAPT Trial



Primary Endpoint: Death, MI, stroke
4.3%, 5.9%
RRR 29%
p<0.001

N Engl J Med 2014;371:2155-66

DAPT Trial

- Requested by FDA
- DES, had not had an event (MI, stroke, revascularization, bleed) and were adherent at 12 months, non-high risk stent diameter, not on warfarin
- Clopidogrel 75 mg (65%) or prasugrel 10 mg (35%) + ASA 75 – 162 mg versus ASA 75 – 162 mg for up to 18 months more
- Efficacy Endpoints – stent thrombosis, CV death/MI/stroke
- Safety Endpoints - Moderate or severe GUSTO bleed
- 9961 were randomized

NEJM 2014;371:2155

DAPT Trial



Figure 2. Cumulative Incidence of Stent Thrombosis, According to Study Group.

N Engl J Med 2014;371:2155-66

DAPT Trial

Population

- 62 y.o. 75% male
- Prior PCI 30%, prior CABG 12%, prior MI 22%
- Non-ACS in 60%

- Type of DES:
  - Sirolimus (Cypher) 11%,
  - Paxlitaxel (TAXUS) 27%
  - Zotarolimus (Endeavor) 12%
  - Everolimus (Xience, PROMUS) 47%

NEJM 2014;371:2155

Pegasus – TIMI 54

- MI 1 – 3 years before enrollment (median 1.7 years)
- 80% underwent PCI
- 50 years of age + 1 risk factor (age > 65, DM, prior MI, multivessel CAD, CrCl < 60 mL/min)
- Excluded: need for anticoagulation, history of bleeding disorder, ischemic stroke, intracranial hemorrhage, GI bleeding in past 6 months, surgery within past 30 days were excluded
- Ticagrelor 90 mg BID, 60 mg BID, or placebo + ASA 75 – 150 mg, median for 33 months
- Efficacy: CV death, MI or stroke
- TIMI major bleeding
- N=21,162

N Engl J Med March 14 2015

CV death, MI or stroke
15% RRR



N Engl J Med March 14 2015

Primary Endpoint: On-Treatment



*N=20,942 patients who received at least one dose of study drug including events through 7 days from the last dose of study drug

Bonaca et al *Circulation* 2015;Abstract

Primary Endpoint – CV Death, MI, or Stroke

Study	Extended DAPT Events	Extended DAPT Total	Aspirin Alone Events	Aspirin Alone Total	Risk Ratio (95% CI)
CHARISMA	125	1903	162	1943	0.77 (0.61 - 0.98)
PRODIGY	63	732	69	733	0.91 (0.65 - 1.28)
ARCTIC-Int'n	3	156	4	167	0.79 (0.18 - 3.51)
DAPT	59	1805	108	1771	0.52 (0.38 - 0.72)
DES-LATE	56	1512	66	1551	0.85 (0.60 - 1.21)
PEGASUS	980	14095	578	7067	0.84 (0.76 - 0.94)
	987	13232			0.78 (0.67 - 0.90)

7.5%

0.2 0.5 1 2

Extended DAPT Better *Aspirin Alone Better*

More Major Bleeding but NO increase in Fatal Bleeding, ICH, non-CV or all-cause death

Udell et al *Eur Heart J* 2016;37:390-99 and *Can J Cardiol* 2015;31:S3